APN (APN) Fair Value & Analysis
Healthcare · Market cap 64.7B ZAC
Fair value as of: Jun 26, 2026
From 14 valuation models · updated 6 days ago
Fair value updated Jun 26, 2026 — revised from R860.36 to R44.26 (−94.9%) since Jun 24, 2026. Share price +8.8% over the past month.
Price vs Fair Value (12 months)
12‑month range R89.16 – R155.35 · fair‑value band R16.47 – R72.05 · the R153.83 price screens above the R44.26 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
APN (APN) currently trades at R153.83, while our model-based Fair Value estimate is R44.26 — implying the stock looks roughly 71.2% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, APN generated revenue of 42.6B ZAR at a net margin of -4.7%. Revenue declined 4.3% year over year. It earns a return on equity of -2.2%. Net debt stands at 29.7B ZAR. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
APN reported revenue of R43.4B in FY2025 versus R37.8B in FY2021, a compound +3.5%/yr. Reported net income was −R1.1B in FY2025.
Is APN fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| 1276 1276 | HK$57.85 | HK$29.84 | -48% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is APN (APN) undervalued?
What is the fair value of APN?
What is the quality score of APN?
What is the revenue of APN (APN)?
What is the net profit margin of APN?
Does APN pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.